Literature DB >> 21486108

Using ECT in schizophrenia: a review from a clinical perspective.

Iannis M Zervas1, Christos Theleritis, Costantin R Soldatos.   

Abstract

OBJECTIVES: Despite the fact that many studies have addressed the use of ECT in schizophrenia questions on clinical use remain poorly answered and clinical application is largely based on data originating from depressed patients.
METHODS: We review data on the use of ECT in schizophrenic patients drawn from original studies indicated by a Pubmed search and referenced in recent and older expert reviews with a specific focus on four issues: symptom response, technical application, continuation/maintenance ECT and combination with medication.
RESULTS: Catatonic patients are the most responsive. Positive symptoms such paranoid delusions and affective symptoms follow. There are indications that ECT may improve responsivity to medication. No particular technical features stand out in studies except lengthier courses, but not for catatonia. Combination with medication appears to be preferable over either treatment alone and effective combination particularly with clozapine is supported by data. Use of continuation and maintenance treatments in responders appears beneficial.
CONCLUSION: Certain schizophrenic patients may benefit significantly from the use of ECT. More specific research is required to address particular questions.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21486108     DOI: 10.3109/15622975.2011.564653

Source DB:  PubMed          Journal:  World J Biol Psychiatry        ISSN: 1562-2975            Impact factor:   4.132


  14 in total

1.  Neuromodulation Treatments for Schizophrenia.

Authors:  Mehmet E Dokucu
Journal:  Curr Treat Options Psychiatry       Date:  2015-07-03

2.  Electroconvulsive therapy: a novel hypothesis for the involvement of purinergic signalling.

Authors:  Ahmed-Ramadan Sadek; Gillian E Knight; Geoffrey Burnstock
Journal:  Purinergic Signal       Date:  2011-06-22       Impact factor: 3.765

3.  Current electroconvulsive therapy practice and research in the geriatric population.

Authors:  Nancy Kerner; Joan Prudic
Journal:  Neuropsychiatry (London)       Date:  2014-02

4.  Autism-Like Behavior in BTBR Mice Is Improved by Electroconvulsive Therapy.

Authors:  Eunice Hagen; Dana Shprung; Elena Minakova; James Washington; Udaya Kumar; Don Shin; Raman Sankar; Andrey Mazarati
Journal:  Neurotherapeutics       Date:  2015-07       Impact factor: 7.620

5.  Current and emergent treatments for symptoms and neurocognitive impairment in schizophrenia.

Authors:  Daniel C Javitt
Journal:  Curr Treat Options Psychiatry       Date:  2015-06

6.  Electroconvulsive Therapy in Women: A Retrospective Study from a Mental Health Hospital in Turkey.

Authors:  Armağan Özdemir; Cana Aksoy Poyraz; Evrim Erten; Emre Çırakoğlu; Nesrin Tomruk
Journal:  Psychiatr Q       Date:  2016-12

7.  Anti-N-methyl-d-aspartate receptor encephalitis in a patient with a 7-year history of being diagnosed as schizophrenia: complexities in diagnosis and treatment.

Authors:  Chaohua Huang; Yukun Kang; Bo Zhang; Bin Li; Changjian Qiu; Shanming Liu; Hongyan Ren; Yanchun Yang; Xiehe Liu; Tao Li; Wanjun Guo
Journal:  Neuropsychiatr Dis Treat       Date:  2015-06-11       Impact factor: 2.570

8.  Patients with schizophrenia or schizoaffective disorder who receive multiple electroconvulsive therapy sessions: characteristics, indications, and results.

Authors:  Iulian Iancu; Nimrod Pick; Orit Seener-Lorsh; Pinhas Dannon
Journal:  Neuropsychiatr Dis Treat       Date:  2015-03-27       Impact factor: 2.570

9.  Factors associated with the risk of relapse in schizophrenic patients after a response to electroconvulsive therapy: a retrospective study.

Authors:  Chiyo Shibasaki; Minoru Takebayashi; Yasutaka Fujita; Shigeto Yamawaki
Journal:  Neuropsychiatr Dis Treat       Date:  2015-01-05       Impact factor: 2.570

Review 10.  Improvement of Psychotic Symptoms and the Role of Tissue Plasminogen Activator.

Authors:  Silvia Hoirisch-Clapauch; Antonio E Nardi
Journal:  Int J Mol Sci       Date:  2015-11-18       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.